AAA
PBYI icon

Affinity Asset Advisors’s Puma Biotechnology PBYI Stock Holding History

Affinity Asset Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-250,000
Closed -$638K – 94
2024
Q3 		$638K Hold
250,000
– – 0.09% 75
2024
Q2 		$815K Buy
+250,000
New +$1.1M 0.09% 83
2024
Q1 		– Sell
-202,349
Closed -$876K – 113
2023
Q4 		$876K Hold
202,349
– – 0.16% 70
2023
Q3 		$532K Hold
202,349
– – 0.15% 71
2023
Q2 		$714K Buy
202,349
+25,000
+14% +$78K 0.25% 58
2023
Q1 		$548K Buy
+177,349
New +$669K 0.18% 65

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Affinity Asset Advisors's PBYI Position: Q4 2024 in Review

Affinity Asset Advisors sold out of Puma Biotechnology (PBYI) in Q4 2024, closing a stake of 250,000 shares — an estimated $638K sold.

Affinity Asset Advisors first reported a position in PBYI in Q1 2023 and held it in 6 quarters. The position peaked at $876K in Q4 2023. 112 funds tracked by Wall St. Rank hold PBYI as of Q4 2024.

  • Affinity Asset Advisors reported no remaining Puma Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Puma Biotechnology shares in Q4 2024, an estimated $638K.
  • Affinity Asset Advisors first reported a position in Puma Biotechnology in Q1 2023 and held it in 6 quarters.
  • Affinity Asset Advisors's Puma Biotechnology position peaked at $876K in Q4 2023.
  • 112 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.